The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
 
Lacey J. Padrón
Patents, Royalties, Other Intellectual Property - Patent pending - U.S. Application No. 63/196,674; Patent pending - U.S. Application No. 63/213,146; Patent pending - U.S. Application No. 63/213,152
 
Deena M. Maurer
No Relationships to Disclose
 
Mark H. O'Hara
Consulting or Advisory Role - Geneos; Natera
Research Funding - Arcus Biosciences; Bristol-Myers Squibb; Celldex; Lilly; Natera; Parker Institute for Cancer Immunotherapy
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
 
Robert A. Wolff
Honoraria - Modern Medicine
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Medscape; PER; PlatformQ Health; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Gritstone Bio; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Advanced Accelerator Applications; Ipsen
Consulting or Advisory Role - Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Aduro Biotech (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply
 
Osama E. Rahma
No Relationships to Disclose
 
Jaclyn P. Lyman
No Relationships to Disclose
 
Christopher R. Cabanski
No Relationships to Disclose
 
Jia Yu
No Relationships to Disclose
 
Shannon M. Pfeiffer
Employment - Genentech/Roche; Genentech/Roche (I)
Stock and Other Ownership Interests - Genentech/Roche (I)
Research Funding - Genentech/Roche (I)
Patents, Royalties, Other Intellectual Property - "Prediction and Characterization of DLBCL COO subtypes" (I)
 
Marko Spasic
Employment - IDEAYA Biosciences
Consulting or Advisory Role - Natera
 
Travis J Hollmann
No Relationships to Disclose
 
Richard Chen
Employment - Personalis
Patents, Royalties, Other Intellectual Property - inventor on the US patent (number 09183496)
 
Jill O'Donnell-Tormey
No Relationships to Disclose
 
Samantha Bucktrout
Stock and Other Ownership Interests - Gilead Sciences; Pfizer; Roche
 
Theresa LaVallee
Employment - Coherus Biosciences
Leadership - Coherus Biosciences; Coherus Biosciences; Lisen Imprinting Diagnostics
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Honoraria - Inovio Pharmaceuticals; NanoString Technologies
Consulting or Advisory Role - BiOneCure; Exosis; Gerson Lehrman Group; Grey Wolf Therapeutics; Immatics; Trex Bio
Patents, Royalties, Other Intellectual Property - Inventor on patents
 
Robert H. Vonderheide
Patents, Royalties, Other Intellectual Property - Inventor on a licensed patient regarding cancer vaccine antigens; Receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody